B+
Bull case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
CLPT
ClearPoint NeuroFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The bull read after earnings is that CLPT delivered record revenue, 16% organic total growth, 25% organic device growth, higher gross margin, and maintained a full-year revenue outlook while pointing to IRRAS revenue and cost synergies in 2H26 [#8-K-2026-05-13].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.0.
What can break
Growth depends in part on partner clinical, regulatory, and funding progress across the biopharma pipeline, which management does not fully control [#10-Q-2026-05-13].
Momentum
31
Value
37
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $17.00 · Bear $7.50Analysis 2026-05-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $23.50
Why
Momentum31 · Δ7d -1.4
Value37 · Δ7d -0.0
Sentiment40 · Δ7d +10.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.0.
Contradictions & invalidation
- • Growth depends in part on partner clinical, regulatory, and funding progress across the biopharma pipeline, which management does not fully control [#10-Q-2026-05-13].
- • IRRAS integration is a key part of the 2026-2027 synergy story; if product uptake or cost synergies slip, the cash-neutrality narrative for 2027 weakens [#8-K-2026-05-13].
- • The bear read is that headline growth still came with an EPS miss versus consensus in post-release coverage, ongoing operating losses, roughly $8.0 million of quarterly operating cash burn, and dependence on partner clinical progress plus successful IRRAS integration.
Catalyst clock
2026-08-15
Q1 print showed strong growth but did not clearly change the monitoring thesis
Lead driver: Sentiment · See AI snapshot
Momentum
31
9% active weight
Current posture
7d trendImproving
Δ7d
-1.4
Δ21d
-15.2
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
40
62% active weight
Current posture
7d trendImproving
Δ7d
+10.0
Δ21d
+9.8
Why this grade
Composite grade F. Momentum 31.1 / Value 36.6 / Sentiment 40.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-16. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$472.82M
Beta
1.02
Shares Out
30.5M
P/E (TTM) · Derived
-17.2
P/S (TTM)
12.30
P/FCF (TTM) · Derived
-14.48
Rev YoY
+18.1%
EPS YoY
+81.9%
Gross Margin
+61.6%
Op Margin
-73.4%
Net Debt
$12.31M
Current Ratio
4.73
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data